{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for dronabinol in Mixture Component Name (approximate match)
Showing 1 - 1 of 1 results
Status:
Possibly Marketed Outside US
Source:
NCT01964547: Phase 4 Interventional Completed Multiple Sclerosis
(2012)
Source URL:
Class:
MIXTURE
Targets:
CB-13 is a cannabinoid drug, which acts as a potent agonist at both the CB1 and CB2 receptors, but has poor blood-brain barrier penetration, and so produces only peripheral effects at low doses, with symptoms of central effects such as catalepsy only appearing at much higher dose ranges. CB-13 displays antihyperalgesic activity in a rat model of neuropathic pain with no CNS side effects.